Affluent Medical SAS (AFME) - Total Liabilities
Based on the latest financial reports, Affluent Medical SAS (AFME) has total liabilities worth €38.73 Million EUR (≈ $45.28 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Affluent Medical SAS - Total Liabilities Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Affluent Medical SAS to evaluate short-term liquidity relative to the company's equity base.
Affluent Medical SAS Competitors by Total Liabilities
The table below lists competitors of Affluent Medical SAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FG Merger II Corp. Unit
NASDAQ:FGMCU
|
USA | $194.92K |
|
Kumho Ind
KO:002990
|
Korea | ₩1.26 Trillion |
|
Next Technology Holding Inc
NASDAQ:NXTT
|
USA | $40.37 Million |
|
FCR Immobilien AG
XETRA:FC9
|
Germany | €277.95 Million |
|
Poongwon Precision Co. Ltd.
KQ:371950
|
Korea | ₩69.54 Billion |
|
An Phat Plastic and Green Environment JSC
VN:AAA
|
Vietnam | ₫6.77 Trillion |
|
Lotus Resources Ltd
AU:LOT
|
Australia | AU$43.91 Million |
|
Woongjin Co Ltd
KO:016880
|
Korea | ₩4.82 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down Affluent Medical SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AFME stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Affluent Medical SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Affluent Medical SAS (2016–2024)
The table below shows the annual total liabilities of Affluent Medical SAS from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €30.59 Million ≈ $35.76 Million |
+21.61% |
| 2023-12-31 | €25.15 Million ≈ $29.40 Million |
-3.96% |
| 2022-12-31 | €26.19 Million ≈ $30.62 Million |
-1.18% |
| 2021-12-31 | €26.50 Million ≈ $30.98 Million |
-10.28% |
| 2020-12-31 | €29.54 Million ≈ $34.53 Million |
-13.86% |
| 2019-12-31 | €34.29 Million ≈ $40.09 Million |
+471.56% |
| 2017-12-31 | €6.00 Million ≈ $7.01 Million |
+110.20% |
| 2016-12-31 | €2.85 Million ≈ $3.34 Million |
-- |
About Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more